SUMMIT THERAPEUTICS INC (SMMT) Stock Fundamental Analysis

NASDAQ:SMMT • US86627T1088

15.8 USD
+0.12 (+0.77%)
At close: Feb 26, 2026
15.72 USD
-0.08 (-0.51%)
After Hours: 2/26/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall SMMT gets a fundamental rating of 2 out of 10. We evaluated SMMT against 521 industry peers in the Biotechnology industry. SMMT has a great financial health rating, but its profitability evaluates not so good. SMMT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SMMT has reported negative net income.
  • SMMT had a negative operating cash flow in the past year.
  • In the past 5 years SMMT always reported negative net income.
  • In the past 5 years SMMT always reported negative operating cash flow.
SMMT Yearly Net Income VS EBIT VS OCF VS FCFSMMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

  • SMMT has a worse Return On Assets (-230.24%) than 90.40% of its industry peers.
  • With a Return On Equity value of -287.57%, SMMT is not doing good in the industry: 72.74% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -230.24%
ROE -287.57%
ROIC N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
SMMT Yearly ROA, ROE, ROICSMMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

  • SMMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMMT Yearly Profit, Operating, Gross MarginsSMMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SMMT Yearly Shares OutstandingSMMT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SMMT Yearly Total Debt VS Total AssetsSMMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 93.65 indicates that SMMT is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 93.65, SMMT belongs to the top of the industry, outperforming 98.66% of the companies in the same industry.
  • There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 93.65
ROIC/WACCN/A
WACCN/A
SMMT Yearly LT Debt VS Equity VS FCFSMMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • SMMT has a Current Ratio of 5.13. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
  • SMMT's Current ratio of 5.13 is in line compared to the rest of the industry. SMMT outperforms 57.01% of its industry peers.
  • A Quick Ratio of 5.13 indicates that SMMT has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.13, SMMT perfoms like the industry average, outperforming 58.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.13
Quick Ratio 5.13
SMMT Yearly Current Assets VS Current LiabilitesSMMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for SMMT have decreased strongly by -161.29% in the last year.
EPS 1Y (TTM)-161.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SMMT will show a very strong growth in Earnings Per Share. The EPS will grow by 42.08% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.73%
EPS Next 2Y-3.92%
EPS Next 3Y30.39%
EPS Next 5Y42.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SMMT Yearly Revenue VS EstimatesSMMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
SMMT Yearly EPS VS EstimatesSMMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SMMT. In the last year negative earnings were reported.
  • Also next year SMMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMMT Price Earnings VS Forward Price EarningsSMMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMMT Per share dataSMMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SMMT's earnings are expected to grow with 30.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.92%
EPS Next 3Y30.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SMMT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (2/26/2026, 8:00:02 PM)

After market: 15.72 -0.08 (-0.51%)

15.8

+0.12 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)04-29
Inst Owners14.44%
Inst Owner Change12.3%
Ins Owners86.05%
Ins Owner Change2.45%
Market Cap11.76B
Revenue(TTM)N/A
Net Income(TTM)-746.08M
Analysts79.13
Price Target33.08 (109.37%)
Short Float %35.6%
Short Ratio13.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.73%
Min EPS beat(2)-24.49%
Max EPS beat(2)3.04%
EPS beat(4)2
Avg EPS beat(4)-8.83%
Min EPS beat(4)-24.49%
Max EPS beat(4)3.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.61%
PT rev (3m)0.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.97%
EPS NY rev (3m)5.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 45.34
P/tB 45.7
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -230.24%
ROE -287.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 475%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.13
Quick Ratio 5.13
Altman-Z 93.65
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.01%
Cap/Depr(5y)64.02%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-161.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
EPS Next Y-16.73%
EPS Next 2Y-3.92%
EPS Next 3Y30.39%
EPS Next 5Y42.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.2%
EBIT Next 3Y-53.79%
EBIT Next 5YN/A
FCF growth 1Y-352.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-352.1%
OCF growth 3YN/A
OCF growth 5YN/A

SUMMIT THERAPEUTICS INC / SMMT FAQ

Can you provide the ChartMill fundamental rating for SUMMIT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SMMT.


Can you provide the valuation status for SUMMIT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to SUMMIT THERAPEUTICS INC (SMMT). This can be considered as Overvalued.


Can you provide the profitability details for SUMMIT THERAPEUTICS INC?

SUMMIT THERAPEUTICS INC (SMMT) has a profitability rating of 0 / 10.


Can you provide the financial health for SMMT stock?

The financial health rating of SUMMIT THERAPEUTICS INC (SMMT) is 7 / 10.